(Q33983198)

30 July 2017

title

Cytoreductive nephrectomy in patients with metastatic non-clear-cell renal cell carcinoma (RCC) (English)

1 reference

30 July 2017

1 reference

6

Toni K Choueiri

1 reference

30 July 2017

4

Adam S Kibel

1 reference

30 July 2017

Ayal A Aizer

1

1 reference

30 July 2017

Yuksel Urun

series ordinal

2

1 reference

30 July 2017

Rana R McKay

series ordinal

3

1 reference

30 July 2017

Paul L Nguyen

series ordinal

5

1 reference

30 July 2017

publication date

14 February 2014

1 reference

30 July 2017

1 reference

30 July 2017

volume

113

1 reference

30 July 2017

issue

5b

1 reference

30 July 2017

page(s)

E67-74

1 reference

30 July 2017

cites work

Cancer statistics, 2012

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4117702

Initial patterns of care with oral targeted therapies for patients with renal cell carcinoma

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4117702

Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4117702

Cytoreductive nephrectomy for kidney cancer with sarcomatoid histology--is up-front resection indicated and, if not, is it avoidable?

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4117702

The role of cytoreductive nephrectomy in the era of molecular targeted therapy

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4117702

Early stage breast cancer treatments for younger Medicare beneficiaries with different disabilities

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4117702

Efficacy of sunitinib and sorafenib in metastatic papillary and chromophobe renal cell carcinoma

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4117702

Sorafenib in advanced clear-cell renal-cell carcinoma

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4117702

Sunitinib versus interferon alfa in metastatic renal-cell carcinoma

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4117702

Cytoreductive nephrectomy in patients with metastatic renal cancer: a combined analysis

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4117702

Treatment outcome and survival associated with metastatic renal cell carcinoma of non-clear-cell histology

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4117702

Nephrectomy followed by interferon alfa-2b compared with interferon alfa-2b alone for metastatic renal-cell cancer

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4117702

Radical nephrectomy plus interferon-alfa-based immunotherapy compared with interferon alfa alone in metastatic renal-cell carcinoma: a randomised trial

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4117702

A new method of classifying prognostic comorbidity in longitudinal studies: development and validation

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4117702

5 July 2018

1 reference

The impact of cytoreductive nephrectomy on survival of patients with metastatic renal cell carcinoma receiving vascular endothelial growth factor targeted therapy

21 January 2018

1 reference

Crossref

Meta-analysis of randomized controlled trials for the incidence and risk of treatment-related mortality in patients with cancer treated with vascular endothelial growth factor tyrosine kinase inhibitors.

21 January 2018

1 reference

Crossref

Better survival in patients with metastasised kidney cancer after nephrectomy: a population-based study in the Netherlands.

21 January 2018

1 reference

Crossref

Comparison of type I and II papillary renal cell carcinoma (RCC) and clear cell RCC.

21 January 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4117702

Competing risk analysis using R: an easy guide for clinicians

29 October 2018

1 reference

12 December 2020

Cytoreductive nephrectomy for metastatic renal cell carcinoma with nonclear cell histology

1 reference

12 December 2020

Population-based Assessment of Survival After Cytoreductive Nephrectomy Versus No Surgery in Patients With Metastatic Renal Cell Carcinoma

1 reference

12 December 2020

A Population-based Analysis of the Rate of Cytoreductive Nephrectomy for Metastatic Renal Cell Carcinoma in the United States

1 reference

12 December 2020

The value of cytoreductive nephrectomy for metastatic renal cell carcinoma in the era of targeted therapy

1 reference

12 December 2020

Identifiers

DOI

10.1111/BJU.12442

1 reference

30 July 2017

1 reference

30 July 2017

1 reference